Beijing Mabworks Biotech Co., Ltd.

This study tests a new medicine called MIL62 in 120 adults with lupus, a chronic autoimmune disease. The goal is to see if MIL62 can reduce disease activity better than a placebo. Participants must have active lupus and be on a stable treatment plan. The study is not a cure but a…

This phase 3 trial tests a drug called MIL62 in 102 people with neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease that attacks the optic nerves and spinal cord. Participants receive MIL62 or a placebo by IV infusion over several months. The main goal is to…